Affecting roughly half a million Americans each year, bacterial infections caused by Clostridioides difficile—commonly known as C. diff—are a serious and persistent problem for patients and hospitals ...

The presence of antigen-specific and neutralizing antibodies was not associated with Clostridioides difficile infection symptoms, severity, therapy approach, treatment response, or recurrences in a ...

Clostridium difficile infection (CDI) is a common hospital-acquired infection that is associated with a high clinical and economic burden. Because of this management of CDI is quickly becoming a part ...

Estimated to cause almost half a million infections per year, the bacterium Clostridioides difficile, also known as C. difficile or "C. diff," can cause diarrhea and inflammation of the large ...

Affecting roughly half a million Americans each year, bacterial infections caused by Clostridioides difficile - commonly known as C. diff - are a serious and persistent problem for patients and ...

Purpose The pharmacology, clinical efficacy, safety, dosage and administration, and place in therapy of fidaxomicin for the treatment of Clostridium difficile infection (CDI) are reviewed. Conclusion ...

Clostridioides difficile (C. diff.) infection (CDI), formerly known as Clostridium difficile infection, is the leading infectious cause of nosocomial diarrhea in North America and Europe and is ...

A new imaging approach used microscopic glowing tags to reveal gene activity in individual C. diff cells in gut tissue samples from infected mice. Here, a resulting image shows a round cross-section ...

The gastrointestinal (GI) microbiota (GIM) plays a central role in human health, including immunomodulation 1,2, influencing inflammation in the GI tract 3 and resistance to pathogen colonization 4.

A study investigating samples of the superbug Clostridioides difficile across 14 pig farms in Denmark finds the sharing of multiple antibiotic-resistance genes between pigs and human patients, ...